Deal Details

Inflexion Makes Minority Investment In Proteros

Healthcare

Inflexion investment in Proteros

Summary

Inflexion has made a minority investment into Proteros Biostructures GmbH (“Proteros”). The transaction is subject to customary regulatory approvals and is expected to close in Q1 2023.

Baird served as the exclusive financial advisor to Inflexion on this transaction.

About

Inflexion is a leading mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth. Inflexion’s flexible approach allows it to back both majority and minority investments, typically investing £10m to £400m of equity in each deal.

Proteros is a specialist in structural biology and has created a cutting-edge platform recognised globally by both large pharma and biotechs as capable of unlocking the most technically challenging drug targets. Proteros supports many of the world’s top 20 largest pharmaceutical companies and over 200 pharma and biotech partners in the United States, Europe and Japan to reach the right results and accelerate their overall research timelines, helping them to lead optimisation and clinical programmes. Proteros was founded in 2000 by Dr Torsten Neuefeind (CEO) and Nobel Laureate Prof. R Huber, and today it boasts leading technologies that enable users to map the shape of a drug target with a high degree of precision.

With the support of Inflexion as a minority investor, Proteros aims to scale globally both organically and through acquisition, particularly in the United States. Proteros also aims to draw on Inflexion’s proven expertise in healthcare and commercial strategy to further strengthen Proteros’ overall value proposition for its blue-chip customer base. Torsten will continue to lead the company as Founder and CEO and retains the majority shareholding in Proteros. Proteros is headquartered in Munich, Germany.

Healthcare

Inflexion investment in Proteros